Brussels, Brussels Hoofdstedelijk Gewest, Belgium UCB Ventures appeared to be the VC, which was created in 2017.
Besides them, we counted 5 critical employees of this fund in our database.
The usual cause for the fund is to invest in rounds with 5 partakers. Despite the UCB Ventures, startups are often financed by The Westly Group, HealthTech Capital, CVSHealth. The meaningful sponsors for the fund in investment in the same round are The Westly Group, Temasek Holdings, Qiming Venture Partners. In the next rounds fund is usually obtained by Muscular Dystrophy Association.
The fund has exact preference in a number of founders of portfolio startups. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Locana, MyHealthTeams. Among the most successful fund investment fields, there are Social Network, Medical.
The fund is generally included in 2-6 deals every year. The high activity for fund was in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 47 percentage points more often commits exit comparing to other companies.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Barings Equity Partners | China, Hong Kong, Hong Kong Island |
| Bpmpartners | Connecticut, Stamford, United States |
| Chunxiao Capital | Beijing, Beijing, China |
| Custodi di successo | Italy, Veneto, Vicenza |
| EIG Global Energy Partners(EIG) | District of Columbia, United States, Washington |
| GAC Capital | Anhui, China, Yuexi |
| HBAN Medtech Syndicate | - |
| International Coach Federation | Kentucky, Lexington, United States |
| Oddo & Cie | Switzerland, Zürich, Zurich |
| Republic | New York, New York, United States |
| Sequoia Scout | - |
| The ALS Association | District of Columbia, United States, Washington |
| Tohoku University Venture Partners | Japan, Miyagi Prefecture, Sendai |
| VEF | Stockholm, Stockholm County, Sweden |
| Woofoo Capital | - |
| Xijie Touzi | China, Shanghai |
| Yuan Capital | China, Hong Kong, Hong Kong Island |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
SomaServe | $27M | 13 Nov 2023 | Cambridge, England, United Kingdom | ||
Switch Therapeutics | $52M | 14 Mar 2023 | San Francisco, California, United States | ||
Code Biotherapeutics | $75M | 07 Jun 2022 | Hatfield, Pennsylvania, United States | ||
Splice Bio | $59M | 15 Feb 2022 | Barcelona, Catalonia, Spain | ||
EsoBiotec | $3M | 30 Sep 2021 | Mont-saint-guibert, Brabant Wallon, Belgium | ||
StrideBio | $81M | 16 Mar 2021 | Durham, North Carolina, United States | ||
| $100M | 14 Dec 2020 | San Diego, California, United States | |||
| $51M | 06 Oct 2020 | Cambridge, Massachusetts, United States | |||
Syndesi Therapeutics | $7M | 28 Sep 2020 | Belgium, Limburg, Belgium |
– ExeVir from Ghent, Belgium develops single domain antibody therapies providing broad protection against viral infections.
– The company closed its Series A financing raising a total of US$50m.
– Led by Fund+, the round was also joined by VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest as well as several Belgian family offices.
– The company is using the funds to commence the global phase 1b/2 clinical trial of lead compound XVR011 and develop a VHH72-Fc sub-cutaneous formulation for Covid-19 in parallel and accelerate development of its pipeline beyond Covid-19 in infectious diseases.
– StrideBio, Inc. is a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated virus (AAV) based gene therapies.
– The company closed a $81.5m Series B funding round.
– Northpond Ventures and Novo Holdings A/S co-led the round with new investors Pontifax, Octagon Capital, Sarepta Therapeutics, CaaS Capital and UF Innovate Ventures joining existing investors Hatteras Venture Partners, UCB Ventures, Takeda Ventures and Alexandria Venture Investments.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
SomaServe | $27M | 13 Nov 2023 | Cambridge, England, United Kingdom | ||
Switch Therapeutics | $52M | 14 Mar 2023 | San Francisco, California, United States | ||
Code Biotherapeutics | $75M | 07 Jun 2022 | Hatfield, Pennsylvania, United States | ||
Splice Bio | $59M | 15 Feb 2022 | Barcelona, Catalonia, Spain | ||
EsoBiotec | $3M | 30 Sep 2021 | Mont-saint-guibert, Brabant Wallon, Belgium | ||
StrideBio | $81M | 16 Mar 2021 | Durham, North Carolina, United States | ||
| $100M | 14 Dec 2020 | San Diego, California, United States | |||
| $51M | 06 Oct 2020 | Cambridge, Massachusetts, United States | |||
Syndesi Therapeutics | $7M | 28 Sep 2020 | Belgium, Limburg, Belgium |
